The University of Texas Southwestern Medical Center (UTSW) has a history of leadership, translational research, and accrual to cooperative group trials. The PI of this grant is Dr. Joan Schiller, chief of the Division of Heme/Oncology and Deputy Director of the Simmons Cancer Center (SCC), former Chair of ECOG's Thoracic Committee and currently PI of UTSW's main institution ECOG grant. Co-investigators include Dr. Hak Choy, Chair of UTSW's Department of Radiation Oncology, Vice Chair for Disease Sites in RTOG, and former Chair of RTOG's Thoracic Committee; Dr. David Miller, member of the GOG Board of Directors and Chair of the Uterine Corpus Committee; Dr. Marilyn Leitch, member of the Executive Committee of ACOSOG, and Dr. Phil Evans, immediate past president of the American Cancer Society, who was one of the founding members of the ACRIN Breast committee, and served as the principal investigator at UTSW for ACRIN sponsored trials. In 2012, UTSW enrolled 105 patients on adult co-operative group trials. Since 2006, UTSW faculty have investigated or co-investigated 96 co-operative group publications and 85 abstracts, and have chaired, co-chaired, or served as cooperative committee chair on 34 cooperative group trials. UTSW is also a site for the NCI Centers Quantitative imaging Excellence. UTSW is the only academic medical center and medical school in the Dallas/Ft. Worth (DFW) Metroplex, the fourth largest metropolitan area in the country, and is the only NCI designated Cancer Center in north Texas. UTSW also has a strong clinical and transitional research program and drug discovery program; a SPORE in lung cancer; an Advanced Imaging Research Center; and has access to a diverse ethnic and racial population. In the DFW Metroplex, roughly 10.3% of the populations with a cancer diagnosis are Hispanic, and 14.1% are African American; in 2012, 29.6% of SCC patients going on co-operative group clinical studies were of Hispanic ethnicity, and 13.6% were of African American ancestry.
The specific aims of the UTSW UIO are to contribute to and promote: (1) The NCTN by enrolling patients with diverse ethnic and racial background on therapeutic and non-therapeutic trials; (2) The scientific direction of the NCTN by bringing the basic, translational, and imaging research conducted at UTSW into hypothesis driven clinical trials. (3) Multidisciplinary efforts and collaboration across multiple disciplinesand multiple cooperative groups; (4) Service in leadership roles by chairing and co-chairing clinical trials and committees, and by participating in NCI activities and initiatives; and (5) The career development of junior faculty.
The University of Texas Southwestern Medical Center brings to the NCTN a history of leadership in multiple cooperative groups and excellent accrual to cooperative group trials, Including ethnic and racial minorities. Other strengths include our innovative basic research and drug discovery which can be translated to clinic research, an Advanced imaging Center, and our unique position as the only NCI designated Cancer Center and academic medical center in the fourth largest metropolitan area in the country.
|Giuliano, Armando E; Ballman, Karla V; McCall, Linda et al. (2017) Effect of Axillary Dissection vs No Axillary Dissection on 10-Year Overall Survival Among Women With Invasive Breast Cancer and Sentinel Node Metastasis: The ACOSOG Z0011 (Alliance) Randomized Clinical Trial. JAMA 318:918-926|
|Garcia, Sandra; Saltarski, Jessica M; Yan, Jingsheng et al. (2017) Time and Effort Required for Tissue Acquisition and Submission in Lung Cancer Clinical Trials. Clin Lung Cancer 18:626-630|
|Chun, Stephen G; Hu, Chen; Choy, Hak et al. (2017) Impact of Intensity-Modulated Radiation Therapy Technique for Locally Advanced Non-Small-Cell Lung Cancer: A Secondary Analysis of the NRG Oncology RTOG 0617 Randomized Clinical Trial. J Clin Oncol 35:56-62|
|Gerber, David E; Urbanic, James J; Langer, Corey et al. (2017) Treatment Design and Rationale for a Randomized Trial of Cisplatin and Etoposide Plus Thoracic Radiotherapy Followed by Nivolumab or Placebo for Locally Advanced Non-Small-Cell Lung Cancer (RTOG 3505). Clin Lung Cancer 18:333-339|
|Halm, Ethan A; Anderson Jr, Larry D; Gerber, David E (2017) Understanding the Relationship Between Care Volume and Clinical Outcomes in Multiple Myeloma. J Clin Oncol 35:580-582|
|Mena, Esther; Taghipour, Mehdi; Sheikhbahaei, Sara et al. (2017) Value of Intratumoral Metabolic Heterogeneity and Quantitative 18F-FDG PET/CT Parameters to Predict Prognosis in Patients With HPV-Positive Primary Oropharyngeal Squamous Cell Carcinoma. Clin Nucl Med 42:e227-e234|
|Reimer, Torsten; Lee, Simon J Craddock; Garcia, Sandra et al. (2017) Cancer Center Clinic and Research Team Perceptions of Identity and Interactions. J Oncol Pract 13:e1021-e1029|
|Pruitt, Sandi L; Laccetti, Andrew L; Xuan, Lei et al. (2017) Revisiting a longstanding clinical trial exclusion criterion: impact of prior cancer in early-stage lung cancer. Br J Cancer 116:717-725|
|Kendi, Ayse Tuba; Brandon, David; Switchenko, Jeffrey et al. (2017) Head and neck PET/CT therapy response interpretation criteria (Hopkins criteria) - external validation study. Am J Nucl Med Mol Imaging 7:174-180|
|Subramaniam, Rathan M (2017) Precision Medicine and PET/Computed Tomography: Challenges and Implementation. PET Clin 12:1-5|
Showing the most recent 10 out of 47 publications